S135 Twice-yearly depemokimab demonstrates efficacy in patients with asthma across baseline medium- and high-dose ICS subgroups: Phase III SWIFT-1/2 studies

Introduction and Objectives Depemokimab is the first ultra-long-acting biologic with enhanced IL-5 binding affinity, high potency, and extended half-life, enabling twice-yearly dosing in patients with asthma. Previously approved biologics are recommended as add-on treatment to high-dose ICS. In SWIFT-1/2, depemokimab significantly reduced exacerbations, with sustained suppression of inflammation as assessed by blood eosinophil count in patients with type 2 asthma. We aimed to assess depemokimab efficacy in SWIFT-1/2 patients by medium- and high-dose ICS subgroup.Methods Patients randomised 2:1 (stratified by medium-/high-dose ICS) with any ACQ-5 score were studied for 52 weeks and received depemokimab 100 mg subcutaneous or placebo at Week 0 and 26, plus standard of care. Pre-specified analyses examined exacerbation rate and change from baseline in St George’s Respiratory Questionnaire (SGRQ) score by baseline ICS dose.Results Depemokimab reduced exacerbations vs placebo by 61% and 49% in patients on medium- and high-dose ICS, respectively ( figure 1). There was a greater SGRQ improvement for depemokimab vs placebo in patients on medium- vs high-dose ICS (figure 1).Conclusions Depemokimab reduces exacerbations in patfients with asthma across baseline ICS dose subgroups, supporting potential initiation prior to ICS escalation.Funding GSK (206713/213744; NCT04719832/NCT04718103).Abstract S135 Figure 1(A) Annualised exacerbation rate and (B) LS mean change from baseline to Week 52 in SGRQ total score in patients receiving depemokimab or placebo stratified by baseline ICS dose (medium/high)